Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| UConn Health | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This 5-year proposal is a randomized study of split-virus influenza vaccine (SVV) in a high-dose (HD) vs. standard-dose (SD) formulation in each of five influenza seasons to define the key determinants of vaccine-mediated protection against influenza and how these immunologic mediators may be enhanced by vaccination with a newly approved high-dose influenza vaccine in older people
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Flu Vaccine SD | Active Comparator | Fluzone Standard Dose Influenza Vaccine |
|
| Flu Vaccine HD | Active Comparator | Fluzone High Dose Influenza Vaccine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Flu Vaccine | Biological |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Influenza Cases | Influenza surveillance includes weekly contact with study subjects to assess for any flu-like symptoms or acute respiratory infection (ARI), and include nasopharyngeal swabs (within 5 days of onset of symptoms) for polymerase chain reaction (PCR) detection of influenza virus and post-influenza season detection of an antibody response to influenza infection. Routine screen for symptoms of ARI will also occur at the 4, 10 and 20 week visits when blood samples are collected. Influenza illness will be documented by PCR detection of influenza during an IARI or seroconversion (4-fold rise in antibody titers) in association with an ARI. ARI includes upper (coryza or sore throat) or lower (cough or shortness of breath) respiratory tract symptoms, or headache, malaise, myalgia or fever (> 99°F or 37.3°C orally or 100°F rectally) [41]. as physician visits, hospitalizations and deaths attributed to acute cardiopulmonary illness and will be tracked through the influenza season. | five years |
Not provided
Not provided
Inclusion Criteria:
Written informed consent provided by the participant
Age 20-40 years old with no underlying chronic diseases or age ≥65 years old
Willing to receive influenza vaccination
Older cohort has received their influenza vaccine for the previous influenza season
-
Exclusion Criteria:
Immunosuppressive disorders or medications (including oral prednisone in doses >10 mg daily)
Have not received influenza vaccination in the past or cannot be vaccinated due to previous severe reaction to influenza vaccine, egg, latex, or thimerosol allergies, or refusal of vaccination
Participant has received a community available influenza vaccine for the approaching influenza season
Females who are pregnant at Visit 1 (a pregnancy test will be administered for all females of child-bearing potential)
-
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janet E McElhaney, MD | Health Sciences North Research Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center on Aging, UConn Health | Farmington | Connecticut | 06030 | United States | ||
| Health Sciences North Research Institute |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35128529 | Derived | McElhaney JE, Verschoor CP, Haynes L, Pawelec G, Loeb M, Andrew MK, Kuchel GA. Key Determinants of Cell-Mediated Immune Responses: A Randomized Trial of High Dose Vs. Standard Dose Split-Virus Influenza Vaccine in Older Adults. Front Aging. 2021 May;2:649110. doi: 10.3389/fragi.2021.649110. Epub 2021 May 21. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D007252 | Influenza Vaccines |
| ID | Term |
|---|---|
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Greater Sudbury |
| Ontario |
| P3E 5J1 |
| Canada |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |